Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial

Michael Organ, Lori Wood, Derek Wilke, Chris Skedgel, Tina Cheng, Scott North, Kara Thompson, Susan Winch, Ricardo Rendon

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.
Original languageEnglish
Pages (from-to)601-605
Number of pages5
JournalAmerican Journal of Clinical Oncology
Issue number6
Publication statusPublished - Dec 2013


  • Aged
  • Aged, 80 and over
  • Costs and Cost Analysis
  • Follow-Up Studies
  • Gonadotropin-Releasing Hormone
  • Humans
  • Male
  • Middle Aged
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant
  • Quality of Life
  • Questionnaires
  • Testosterone
  • Treatment Outcome

Cite this